Valeritas V-Go® Wearable Insulin Delivery device has been found to be beneficial compared to conventional insulin delivery in patients with type 2 diabetes. In a study published in the journal Research and Social Administrative Pharmacy, V-Go, a simple, all-in-one, wearable insulin delivery option for patients with diabetes demonstrated significant clinical and economic benefits compared with conventional insulin delivery systems.
Related Insulet Wins FDA Approval for Omnipod DASH Insulin Management System
There have been major advancements in insulin delivery options over the years, but questions remain regarding whether persistent use of these latest devices offer benefits over the conventional insulin delivery (CID) methods of syringes or insulin pen devices, said a press release.
The new study showed that when patients continuously used V-Go, their clinical outcomes significantly improved compared to patients who returned to CID methods after trialing V-Go. The study also showed after an average of 7 to 8 months of continuous use, patients needed lower prescribed insulin doses (62 vs. 92 units/day) and greater A1c reductions (1.4% vs. 0.2%), respectively, compared to those who used V-Go for shorter period and then returned to CID methods. Importantly, patients using V-Go had a lower incremental cost by $695.61 per 1% change in A1c compared to CID patients.
“We are very encouraged with both the clinical and economic benefits patients experienced in our study while utilizing V-Go to manage their diabetes,” said Beverly Everitt, APRN, MSN, CDE, BC-ADM, lead author and investigator from Endocrinology Consultants, Virginia Beach, Virginia. “In my opinion, great consideration should be given to the use of V-Go for the management of patients requiring insulin therapy, given the improvements over conventional insulin delivery in glycemic control and economic outcomes.”
Related JDRF Partners with Korean Company to Develop Wearable Insulin Pump
About Valeritas Holdings
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.
